Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Angiotensin; related peptides
Reexamination Certificate
2002-10-11
2009-06-30
Kosar, Andrew D (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Angiotensin; related peptides
C514S015800, C530S328000, C435S369000
Reexamination Certificate
active
07553928
ABSTRACT:
The present invention relates generally to a method for the treatment and/or prophylaxis of renal-related disorders. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of glomerulosclerosis and/or end stage renal failure and/or related conditions. The method of the present invention is preferably practised by the administration of a derivative of angiotensin I. Generally, but not exclusively, the angiotensin I derivative exhibits anti-angiotensin II properties. In a preferred embodiment, the angiotensin I is des-Aspartate-angiotensin I or a derivative, homologue or analogue thereof. The present invention further contemplates compositions for use in the treatment and/or prophylaxis of renal-related disorders such as but not limited to glomerulosclerosis and/or end stage renal failure.
REFERENCES:
patent: 5773415 (1998-06-01), Sim
patent: 5854388 (1998-12-01), Harding et al.
patent: 6100237 (2000-08-01), Sim
patent: 2004/0265882 (2004-12-01), McGrail et al.
patent: WO 99/40106 (1999-08-01), None
The Kidney Disease Dictionary, American Kidney Fund, pp. 1-12, pttp://www.kidneyfund.org/facts—dictionary.asp, printed Sep. 26, 2005.
Schieppati, et al., Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications, Kidney International, 2005, vol. 68, Supplement 98, pp. S7-S10.
Bello, et al., Prevention of chronic kidney disease: A global challenge, Kidney International , vol. 68 Supplement 98, pp. S11-S17.
Bos, Do severe systemic sequelae of proteinuria modulate the antiproteinuria response to chronic ACE inhibition? Nephrology Dialysis Transplantation 2002, vol. 17, pp. 793-797.
Ander, et al., Murine Models of Renal Disease: possibilties and problem in Studies Using Mutant Mice, experimental Nephrology, 2000, vol. 8, p. 181-193.
Chen, et al., (Regulatory Peptides (2002) 106:39-46).
Voet (D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241).
Rudikoff, et al., (PNAS, 1982, 79, 1979-1983).
[Information retrieved from] http:www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm, 4 pages [Retrieved on Jan. 17, 2007].
Agrawal, 2000, American Family Physician, 61, 2077-2088.
Min, L., et al. “Effects of des-aspartate-angiotensin I on angiotensin II-induced incorporation of phenylalanine and thymidine in cultured rat cardiomyocytes and aortic smooth muscle cells,”0Regulatory Peptides, 95:93-97, 2000.
Lim, B.C., et al. “Actions of des-asp-angiotensin I on the aortic rings of the normo- and hypertensive rats,”Clin. and Exper. Hypertension, 20(1):105-117, 1998.
Sim, M.K., et al. “Determination of aminopeptidase X activity in tissues of normo- and hypertensive rats by capillary electrophoresis,”Journal of Chromatography B, 697:259-262, 1997.
Radhakrishnan, R., et al. “Actions of D-amino acid-substituted analogues of des-Asp-angiotensin I on the central pressor action of angiotensin III,”European Journal of Pharmacology, 294:337-339, 1995.
Sim, M.K., et al. “Effects of des-Asp-angiotension I on experimentally-induced cardiac hypertrophy in rats,”International Journal of Cardiology, 63:223-227, 1998.
Sim, M.K., et al. “Novel central action of des-Asp-angiotensin I,”European Journal of Pharmacology, 257:R1-R3, 1994.
Ashton B. Morrison “Experimental Chronic Renal Insufficiency”, (1966)Meth. Achievm. exp. Path., vol. 1, pp. 455-475.
Blair-West et al. “The Effect of the Heptapeptide (208) and Hexapeptide (3-8) Fragments of Angiotensin II on Aldosterone Secretion”, (1971)J. Clin. Endocrinol. Metab. 32:275.
Tsai et al. “Synthesis and Evaluation of [Des-Asp1]angiotensin I as a Precursor for [Des-Asp1]angiotensin II (“Angiotensin III”)”, (1975)J. Med. Chem. 18:1180.
Sim and Chai “Subtypes of losartar-sensitive angiotensin receptor in the rabbit pulmonary artery”, (1996)Br J. Pharmacol. 117-1504.
Hamar et al., “Coinhibition of Immune and Renin-Angiotensin Systems Reduces the Pace of Glomerulosclerosis in the Rat Remnant Kidney”, (1999)J. Am. Soc. Nephrol. 10:S234-S238.
Nakamura et al., “Involvement of angiotensin II in glomerulosclerosis of stroke-prone spontaneously hypertensive rats”,Kidney International, vol. 49, Suppl. 55 (1996), pp. S-109-S-112.
Kettler et al., “Transforming Growth Factor-β and Angiotensin II: The Missing Link from Glomerular Hyperfiltration to Glomerulosclerosis”,Annu. Rev. Physiol. 1995, 57:279-95.
Strauch et al., “Animal Models to Induce Renal Failure: A Historical Survey”,Contr. Nephrol., vol. 60, pp. 1-8 (Karger, Basel 1988).
Ashton B. Morrison, M.D., Ph.D., “Experimentally Induced Chronic Renal Insufficiency in the Rat”,Laboratory Investigation, vol. 11, No. 4, 1962.
Jagger, Paul I. et al., “Hypertensive Vascular Disease,” Wintrose, MW et al, editors,Harrison's Principles of Internal Medicine, 7thEd., pp. 1236-1240, 1974.
Sim Meng Kwoon
Tan Chorh Chuan
Gudibande Satyanarayana R
Klarquist & Sparkman, LLP
Kosar Andrew D
National University of Singapore
LandOfFree
Use of des-Aspartate-angiotensin I as an agent for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of des-Aspartate-angiotensin I as an agent for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of des-Aspartate-angiotensin I as an agent for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090754